Advertisement
Screener

FATE THERAPEUTICS INC (FATE) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

FATE THERAPEUTICS INC Stock-Based Compensation

FATE THERAPEUTICS INC (FATE) reported Stock-Based Compensation of $3.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-13

  • FATE THERAPEUTICS INC share-based payment arrangement, expense for the quarter ending 2026-06-30 was $3.52M, a 50.82% decline year-over-year.
  • FATE THERAPEUTICS INC share-based payment arrangement, expense for the quarter ending 2026-03-31 was $3.93M, a 46.77% decline year-over-year.
  • FATE THERAPEUTICS INC share-based payment arrangement, expense for the quarter ending 2025-12-31 was $5.53M, a 39.39% decline year-over-year.
  • FATE THERAPEUTICS INC share-based payment arrangement, expense for the quarter ending 2025-09-30 was $4.86M, a 58.68% decline year-over-year.
  • FATE THERAPEUTICS INC share-based payment arrangement, expense for fiscal 2025 was $24.92M, a 39.94% decline from fiscal 2024.
  • FATE THERAPEUTICS INC share-based payment arrangement, expense for fiscal 2024 was $41.50M, a 4.52% decline from fiscal 2023.
  • FATE THERAPEUTICS INC share-based payment arrangement, expense for fiscal 2023 was $43.46M, a 44.80% decline from fiscal 2022.
  • FATE THERAPEUTICS INC share-based payment arrangement, expense for fiscal 2022 was $78.73M, a 44.83% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Expense 3 monthShare-based Payment Arrangement, Expense 6 monthShare-based Payment Arrangement, Expense 9 monthShare-based Payment Arrangement, Expense 12 monthShare-based Payment Arrangement, Expense 80 month
2026-06-30$3.52M
10-Q · filed 2026-08-13
$7.45M
10-Q · filed 2026-08-13
$12.97M
derived: sum of 3 quarters · filed 2026-08-13
$17.84M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$3.93M
10-Q · filed 2026-05-13
$9.46M
derived: sum of 2 quarters · filed 2026-05-13
$14.32M
derived: sum of 3 quarters · filed 2026-05-13
$21.47M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$5.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$10.39M
derived: sum of 2 quarters · filed 2026-02-26
$17.54M
derived: sum of 3 quarters · filed 2026-08-13
$24.92M
10-K · filed 2026-02-26
2025-09-30$4.86M
10-Q · filed 2025-11-13
$12.02M
derived: sum of 2 quarters · filed 2026-08-13
$19.40M
10-Q · filed 2025-11-13
$28.52M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$7.15M
10-Q · filed 2026-08-13
$14.54M
10-Q · filed 2026-08-13
$23.66M
derived: sum of 3 quarters · filed 2026-08-13
$35.42M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$7.38M
10-Q · filed 2026-05-13
$16.50M
derived: sum of 2 quarters · filed 2026-05-13
$28.27M
derived: sum of 3 quarters · filed 2026-05-13
$37.90M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$9.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$20.89M
derived: sum of 2 quarters · filed 2026-02-26
$30.52M
derived: sum of 3 quarters · filed 2026-02-26
$41.50M
10-K · filed 2026-02-26
2024-09-30$11.77M
10-Q · filed 2025-11-13
$21.39M
derived: sum of 2 quarters · filed 2025-11-13
$32.38M
10-Q · filed 2025-11-13
$41.85M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$9.63M
10-Q · filed 2025-08-12
$20.61M
10-Q · filed 2025-08-12
$30.09M
derived: sum of 3 quarters · filed 2025-08-12
$40.19M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$10.98M
10-Q · filed 2025-05-13
$20.46M
derived: sum of 2 quarters · filed 2025-05-13
$30.56M
derived: sum of 3 quarters · filed 2025-05-13
$43.46M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$9.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05
$19.58M
derived: sum of 2 quarters · filed 2025-03-05
$32.48M
derived: sum of 3 quarters · filed 2025-03-05
$43.46M
10-K · filed 2025-03-05
2023-09-30$10.10M
10-Q · filed 2024-11-12
$23.00M
derived: sum of 2 quarters · filed 2024-11-12
$33.98M
10-Q · filed 2024-11-12
$53.38M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$12.90M
10-Q · filed 2024-08-13
$23.88M
10-Q · filed 2024-08-13
$43.27M
derived: sum of 3 quarters · filed 2024-08-13
$62.74M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$10.98M
10-Q · filed 2024-05-09
$30.38M
derived: sum of 2 quarters · filed 2024-05-09
$49.84M
derived: sum of 3 quarters · filed 2024-05-09
$70.39M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$19.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26
$38.86M
derived: sum of 2 quarters · filed 2024-02-26
$59.40M
derived: sum of 3 quarters · filed 2024-02-26
$78.73M
10-K · filed 2024-02-26
2022-09-30$19.47M
10-Q · filed 2023-11-08
$40.01M
derived: sum of 2 quarters · filed 2023-11-08
$59.34M
10-Q · filed 2023-11-08
$73.94M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$20.54M
10-Q · filed 2023-08-08
$39.87M
10-Q · filed 2023-08-08
$54.47M
derived: sum of 3 quarters · filed 2023-08-08
$68.01M
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31$19.33M
10-Q · filed 2023-05-03
$33.92M
derived: sum of 2 quarters · filed 2023-05-03
$47.47M
derived: sum of 3 quarters · filed 2023-05-03
$60.72M
derived: sum of 4 quarters · filed 2023-05-03
2021-12-31$14.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$28.13M
derived: sum of 2 quarters · filed 2023-02-28
$41.39M
derived: sum of 3 quarters · filed 2023-02-28
$54.36M
10-K · filed 2023-02-28
2021-09-30$13.54M
10-Q · filed 2022-11-03
$26.79M
derived: sum of 2 quarters · filed 2022-11-03
$39.77M
10-Q · filed 2022-11-03
$48.53M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$13.25M
10-Q · filed 2022-08-03
$26.23M
10-Q · filed 2022-08-03
$34.99M
derived: sum of 3 quarters · filed 2023-02-28
$42.83M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$12.98M
10-Q · filed 2022-05-04
$21.74M
derived: sum of 2 quarters · filed 2023-02-28
$29.58M
derived: sum of 3 quarters · filed 2023-02-28
$36.82M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$8.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$16.60M
derived: sum of 2 quarters · filed 2023-02-28
$23.84M
derived: sum of 3 quarters · filed 2023-02-28
$30.75M
10-K · filed 2023-02-28
2020-09-30$7.84M
10-Q · filed 2021-11-04
$15.08M
derived: sum of 2 quarters · filed 2021-11-04
$21.99M
10-Q · filed 2021-11-04
$26.57M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30$7.24M
10-Q · filed 2021-08-04
$14.15M
10-Q · filed 2021-08-04
$18.73M
derived: sum of 3 quarters · filed 2022-02-28
$23.30M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$6.91M
10-Q · filed 2021-05-05
$11.50M
derived: sum of 2 quarters · filed 2022-02-28
$16.07M
derived: sum of 3 quarters · filed 2022-02-28
$20.45M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$4.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$9.16M
derived: sum of 2 quarters · filed 2022-02-28
$13.54M
derived: sum of 3 quarters · filed 2022-02-28
$17.41M
10-K · filed 2022-02-28
2019-09-30$4.57M
10-Q · filed 2020-11-05
$8.96M
derived: sum of 2 quarters · filed 2020-11-05
$12.83M
10-Q · filed 2020-11-05
$14.61M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30$4.39M
10-Q · filed 2020-08-05
$8.25M
10-Q · filed 2020-08-05
$10.04M
derived: sum of 3 quarters · filed 2021-02-24
$11.68M
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31$3.87M
10-Q · filed 2020-05-11
$5.65M
derived: sum of 2 quarters · filed 2021-02-24
$7.29M
derived: sum of 3 quarters · filed 2021-02-24
$8.78M
derived: sum of 4 quarters · filed 2021-02-24
2018-12-31$1.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$3.43M
derived: sum of 2 quarters · filed 2021-02-24
$4.91M
derived: sum of 3 quarters · filed 2021-02-24
$6.29M
10-K · filed 2021-02-24
2018-09-30$1.64M
10-Q · filed 2019-11-05
$3.13M
derived: sum of 2 quarters · filed 2019-11-05
$4.51M
10-Q · filed 2019-11-05
$5.40M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30$1.49M
10-Q · filed 2019-08-06
$2.87M
10-Q · filed 2019-08-06
$3.76M
derived: sum of 3 quarters · filed 2020-03-02
$4.63M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31$1.38M
10-Q · filed 2019-05-07
$2.28M
derived: sum of 2 quarters · filed 2020-03-02
$3.15M
derived: sum of 3 quarters · filed 2020-03-02
$4.12M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31$895.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$1.77M
derived: sum of 2 quarters · filed 2020-03-02
$2.74M
derived: sum of 3 quarters · filed 2020-03-02
$3.61M
10-K · filed 2020-03-02
2017-09-30$871.00K
10-Q · filed 2018-11-01
$1.84M
derived: sum of 2 quarters · filed 2018-11-01
$2.71M
10-Q · filed 2018-11-01
$3.53M
derived: sum of 4 quarters · filed 2019-03-05
2017-06-30$973.00K
10-Q · filed 2018-08-06
$1.84M
10-Q · filed 2018-08-06
$2.66M
derived: sum of 3 quarters · filed 2019-03-05
$3.44M
derived: sum of 4 quarters · filed 2019-03-05
2017-03-31$867.00K
10-Q · filed 2018-05-10
$1.69M
derived: sum of 2 quarters · filed 2019-03-05
$2.47M
derived: sum of 3 quarters · filed 2019-03-05
$3.25M
derived: sum of 4 quarters · filed 2019-03-05
2016-12-31$819.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05
$1.60M
derived: sum of 2 quarters · filed 2019-03-05
$2.39M
derived: sum of 3 quarters · filed 2019-03-05
$3.18M
10-K · filed 2019-03-05
2016-09-30$783.00K
10-Q · filed 2017-11-01
$1.57M
derived: sum of 2 quarters · filed 2017-11-01
$2.37M
10-Q · filed 2017-11-01
$2.85M
derived: sum of 4 quarters · filed 2018-03-05
2016-06-30$786.00K
10-Q · filed 2017-08-14
$1.58M
10-Q · filed 2017-08-14
$2.06M
derived: sum of 3 quarters · filed 2018-03-05
$2.64M
derived: sum of 4 quarters · filed 2018-03-05
2016-03-31$797.00K
10-Q · filed 2017-05-15
$1.28M
derived: sum of 2 quarters · filed 2018-03-05
$1.85M
derived: sum of 3 quarters · filed 2018-03-05
$2.59M
derived: sum of 4 quarters · filed 2018-03-05
2015-12-31$480.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05
$1.05M
derived: sum of 2 quarters · filed 2018-03-05
$1.79M
derived: sum of 3 quarters · filed 2018-03-05
$2.40M
10-K · filed 2018-03-05
2015-09-30$574.00K
10-Q · filed 2016-11-07
$1.31M
derived: sum of 2 quarters · filed 2016-11-07
$1.92M
10-Q · filed 2016-11-07
$2.53M
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30$738.00K
10-Q · filed 2016-08-08
$1.35M
10-Q · filed 2016-08-08
$1.96M
derived: sum of 3 quarters · filed 2017-03-16
$2.48M
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31$608.00K
10-Q · filed 2016-05-09
$1.22M
derived: sum of 2 quarters · filed 2017-03-16
$1.75M
derived: sum of 3 quarters · filed 2017-03-16
$2.17M
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31$612.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
$1.14M
derived: sum of 2 quarters · filed 2017-03-16
$1.56M
derived: sum of 3 quarters · filed 2017-03-16
$2.43M
10-K · filed 2017-03-16
2014-09-30$527.00K
10-Q · filed 2015-11-03
$951.00K
derived: sum of 2 quarters · filed 2015-11-03
$1.82M
10-Q · filed 2015-11-03
$2.21M
derived: sum of 4 quarters · filed 2016-03-03
2014-06-30$424.00K
10-Q · filed 2015-08-05
$1.29M
10-Q · filed 2015-08-05
$1.68M
derived: sum of 3 quarters · filed 2016-03-03
$2.66M
derived: sum of 4 quarters · filed 2016-03-03
2014-03-31$871.00K
10-Q · filed 2015-05-07
$1.26M
derived: sum of 2 quarters · filed 2016-03-03
$2.24M
derived: sum of 3 quarters · filed 2016-03-03
$2.35M
derived: sum of 4 quarters · filed 2016-03-03
2013-12-31$385.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03
$1.37M
derived: sum of 2 quarters · filed 2016-03-03
$1.48M
derived: sum of 3 quarters · filed 2016-03-03
$1.55M
10-K · filed 2016-03-03
$2.32M
10-K · filed 2014-03-17
2013-09-30$982.00K
10-Q · filed 2014-11-12
$1.09M
derived: sum of 2 quarters · filed 2014-11-12
$1.17M
10-Q · filed 2014-11-12
2013-06-30$112.00K
10-Q · filed 2014-08-12
$187.00K
10-Q · filed 2014-08-12
2013-03-31$75.00K
10-Q · filed 2014-05-13
2012-12-31$155.00K
10-K · filed 2015-03-12
2011-12-31$172.00K
10-K · filed 2014-03-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35